• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Kimberly Clark (KMB) Buys Kenvue To Build A Bigger Essential Health Business

    Simply Wall St·07/26/2026 07:16:25
    Listen to the news
    • Kimberly-Clark (NasdaqGS:KMB) is acquiring Kenvue, Johnson & Johnson's consumer health business.
    • The deal brings a broad portfolio of essential health product brands under Kimberly-Clark's control.
    • The transaction is expected to reshape Kimberly-Clark's position in higher margin consumer health categories.

    Kimberly-Clark enters this Kenvue deal with its stock at $109.7 and a mixed return profile, including an 8.2% gain year to date and a decline of 9.7% over the past year. Returns over 3 and 5 years have also been weaker, with the stock down 5.1% and 2.1% across those periods. This shift toward higher margin health products is therefore an important development to watch for existing and prospective shareholders.

    The acquisition of Kenvue gives Kimberly-Clark a bigger role in essential health products, an area where brand strength and scale matter. Investors can now focus on how well the company integrates these assets, manages costs, and positions the combined portfolio to support margins and revenue over time.

    Stay updated on the most important news stories for Kimberly-Clark by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Kimberly-Clark.

    NasdaqGS:KMB Earnings & Revenue Growth as at Jul 2026
    NasdaqGS:KMB Earnings & Revenue Growth as at Jul 2026

    2 things going right for Kimberly-Clark that this headline doesn't cover.

    Quick Assessment

    • ⚖️ Price vs Analyst Target: Kimberly-Clark trades at US$109.70 versus a US$117.00 analyst target, about 6% below consensus.
    • ✅ Simply Wall St Valuation: The stock is described as trading 32.4% below an estimated fair value, which flags it as undervalued in that model.
    • ⚖️ Recent Momentum: A 30 day return of 0.3% suggests the price has been relatively flat while this Kenvue deal is in focus.

    There's only one way to know the right time to buy, sell or hold Kimberly-Clark. Head to Simply Wall St's company report for the latest analysis of Kimberly-Clark's Fair Value.

    Key Considerations

    • 📊 The Kenvue acquisition shifts Kimberly-Clark further into higher margin essential health products, which could change how investors view its earnings mix.
    • 📊 Watch how management updates revenue, margin and integration cost guidance as the combined business is reported over coming quarters.
    • ⚠️ There are flagged risks around dividend coverage and debt levels, so consider how deal financing and ongoing payouts interact with these existing pressure points.

    Dig Deeper

    For the full picture including more risks and rewards, check out the complete Kimberly-Clark analysis. Alternatively, you can check out the community page for Kimberly-Clark to see how other investors believe this latest news will impact the company's narrative.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.